Bioinspired Peptide Hydrogel Accelerates Healing of Infected Wounds
Background
Infected wounds pose a significant global health challenge, often leading to prolonged hospitalization, increased morbidity, and even mortality. Current treatments, including antibiotics and conventional dressings, frequently struggle with issues like antibiotic resistance, slow healing rates, and insufficient tissue regeneration. There is a critical need for advanced wound dressings that can effectively combat bacterial infection while simultaneously promoting rapid and high-quality tissue repair.
Results
The AMP-Hydrogel treatment demonstrated superior therapeutic outcomes compared to both control groups. By day 14, the AMP-Hydrogel group achieved 98% wound closure, significantly outperforming the saline control (62% closure) and the Mupirocin group (85% closure), representing a 36% and 13% improvement, respectively. Bacterial load in the AMP-Hydrogel treated wounds was reduced by over 4-log units (99.99% reduction) compared to the saline control by day 7, and was comparable to the Mupirocin group. Histopathological analysis revealed a 3.2-fold increase in collagen deposition and enhanced re-epithelialization in the AMP-Hydrogel group by day 14, alongside a 60% reduction in inflammatory cell infiltration compared to the saline control. Furthermore, the AMP-Hydrogel group showed a 2.8-fold increase in VEGF (vascular endothelial growth factor, a protein promoting new blood vessel growth) expression, indicating accelerated angiogenesis.
Why It Matters
This study highlights the potential of bioinspired antimicrobial peptide hydrogels as a highly effective, dual-action solution for infected wounds, addressing both microbial burden and tissue regeneration. The ability of AMP-Hydrogel to significantly accelerate wound closure, reduce bacterial load, and promote tissue repair simultaneously represents a substantial advancement over conventional treatments. This technology holds significant promise for clinical translation as a superior wound dressing, particularly in an era of increasing antibiotic resistance. Future research should focus on comprehensive toxicology studies and larger animal models before progressing to human clinical trials (Phase I/II) to validate its safety and efficacy in diverse wound types.